FDA staff question dosing of Sanofi combination diabetes drug

May 23, 2016 12:49 PM

18 0

May 23 A preliminary review by the U.S. Food and Drug Administration questioned whether Sanofi SA's experimental drug lixisenatide contributed any benefit to a fixed-dose combination diabetes product the company hopes to market.

The review comes ahead of a May 25 meeting of an FDA advisory panel that will meet to discuss the drug and recommend whether it should be approved.

Also read: Trump Turns to Schwarzman, Dimon for White House Panel on Jobs

Read more

To category page

Loading...